User:Mr. Ibrahem/Fedratinib

Fedratinib, sold under the brand name Inrebic, is a medication used to treat myelofibrosis. This includes primary myelofibrosis, post-polycythaemia vera myelofibrosis, and post-essential thrombocythaemia myelofibrosis. It is used when there is an enlarged spleen or other symptoms. It is taken by mouth.

Common side effects include diarrhea, nausea, low red blood cells, and low platelets. Other side effects may include encephalopathy. It is an inhibitor of Janus kinase 2 (JAK-2) and FLT-3.

Fedratinib was approved for medical use in the United States in 2019 and Europe in 2021. In the United Kingdom a month of medication costs the NHS about £6,100 as of 2021. This amount in the United States costs about 21,300 USD.